David Flores, MD
Urology · Coeur D Alene, IDNPI 1972892669
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,732 of the $3,056 with a category attached, or 89.4%. It is spread thinly across 31 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for urology clinicians in ID, where the typical reported total is $3,075.
Across 128 payments — averaging $23.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$481
- Procept Biorobotics Corporation$372
- AbbVie$308
- Boston Scientific$245
- Sumitomo Pharma America, Inc.$220
- Johnson & Johnson$216
- plus $1K from 25 others
What the payments were for
- Travel & lodging$2137%
- Food & beverage$2,73289%
- Education$1104%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 26 | $481 |
| Procept Biorobotics Corporation | 6 | $372 |
| AbbVie(2 entities) | 16 | $308 |
| Boston Scientific | 6 | $245 |
| Sumitomo Pharma America, Inc. | 8 | $220 |
| Johnson & Johnson | 7 | $216 |
| Pfizer | 9 | $178 |
| Sun Pharmaceutical Industries Inc. | 4 | $121 |
| Olympus America Inc. | 5 | $101 |
| Dendreon Pharmaceuticals LLC | 5 | $97 |
| Laborie Medical Technologies Corp. | 3 | $80 |
| Myriad Genetic Laboratories, Inc. | 3 | $60 |
| Urovant Sciences Inc | 2 | $59 |
| Endo Pharmaceuticals Inc. | 3 | $55 |
| EDAP Technomed Inc | 3 | $54 |
| Travere Therapeutics, Inc. | 5 | $50 |
| Endo USA, Inc. | 2 | $49 |
| Dornier Medtech America, Inc | 1 | $35 |
| Uroviu Corporation | 1 | $34 |
| Bayer | 2 | $32 |
| Urogen Pharma, Inc. | 1 | $26 |
| Telix Pharmaceuticals | 1 | $24 |
| Immunitybio, Inc. | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $21 |
| Tolmar, Inc. | 1 | $21 |
| Tolmar Pharmaceuticals, Inc. | 1 | $21 |
| Verity Pharmaceuticals Inc. | 1 | $18 |
| Axonics, Inc. | 1 | $17 |
| Amgen | 1 | $14 |
| Novartis | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,056 in reported general payments places this provider in the 45th percentile of 55 urology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 107 | $1,448,210 |
| OrgovyxRelugolix | 229 | $588,123 |
| ErleadaApalutamide | 13 | $194,235 |
| NubeqaDarolutamide | 13 | $165,012 |
| Abiraterone Acetate | 55 | $75,122 |
| MyrbetriqMirabegron | 104 | $65,782 |
| GemtesaVibegron | 49 | $31,426 |
| Tamsulosin Hcl | 498 | $7,884 |
| Testosterone | 12 | $4,564 |
| Finasteride | 281 | $3,995 |
| Silodosin | 43 | $3,478 |
| Estradiol | 17 | $2,282 |
| Trospium Chloride | 14 | $2,178 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 75 | $1,488 |
| GlydoLidocaine Hcl | 11 | $630 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $481 | $1,513,992211 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $220 | $619,549278 claims |
| Johnson & JohnsonErleada | $216 | $194,23513 claims |
| BayerNubeqa | $32 | $165,01213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 55 urology providers in Idaho.
Other urology in Coeur D Alene
- Chad PetersonCoeur D Alene$7K
- Matthew McLaughlinCoeur D Alene$6K
- Roxanne HaslamCoeur D Alene$3K
- Sean StroupBoise$93K
- Zachary GlaserTwin Falls$15K
- Wade MunceyMeridian$9K
- John GreerMeridian$8K
- Dawn KingMeridian$8K
- Edward EllisonCoeur D' Alene$7K
- Robert JacksonBoise$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.